Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2002008202) ALPHA AMINO ACID DERIVATIVES--INHIBITORS OF LEUKOCYTE ADHESION MEDIATED BY VLA-4
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2002/008202 International Application No.: PCT/US2001/023075
Publication Date: 31.01.2002 International Filing Date: 20.07.2001
Chapter 2 Demand Filed: 09.01.2002
IPC:
C07D 239/48 (2006.01) ,C07D 239/52 (2006.01) ,C07D 401/12 (2006.01) ,C07D 417/12 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
239
Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
02
not condensed with other rings
24
having three or more double bonds between ring members or between ring members and non-ring members
28
with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
46
Two or more oxygen, sulfur or nitrogen atoms
48
Two nitrogen atoms
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
239
Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
02
not condensed with other rings
24
having three or more double bonds between ring members or between ring members and non-ring members
28
with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
46
Two or more oxygen, sulfur or nitrogen atoms
52
Two oxygen atoms
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02
containing two hetero rings
12
linked by a chain containing hetero atoms as chain links
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
417
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/196
02
containing two hetero rings
12
linked by a chain containing hetero atoms as chain links
Applicants:
ELAN PHARMACEUTICALS, INC. [US/US]; 800 Gateway Blvd. South San Francisco, CA 94080, US
WYETH [US/US]; 5 Giraldi Farms Madison, NJ 07940, US
Inventors:
KONRADI, Andrei, W.; US
PLEISS, Michael, A.; US
THORSETT, Eugene, D.; US
ASHWELL, Susan; US
WELMAKER, Gregory, S.; US
KREFT, Anthony; US
SARANTAKIS, Dimitrios; US
DRESSEN, Darren, B.; US
GRANT, Francine, S.; US
SEMKO, Christopher; US
XU, Ying-Zi; US
Agent:
SWISS, Gerald, F.; Burns, Doane, Swecker & Mathis, L.L.P. P.O. BOX 1404 Alexandria, VA 22313-1404, US
Priority Data:
60/220,13221.07.2000US
Title (EN) ALPHA AMINO ACID DERIVATIVES--INHIBITORS OF LEUKOCYTE ADHESION MEDIATED BY VLA-4
(FR) DERIVES D'ACIDE ALPHA-AMINE, UTILISES COMME INHIBITEURS DE L'ADHESION LEUCOCYTAIRE A MEDIATION PAR VLA-4
Abstract:
(EN) Disclosed are certain alpha amino acid compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
(FR) Cette invention se rapporte à certains composés d'acide alpha-aminé qui fixent VLA-4. Certains de ces composés inhibent également l'adhésion leucocytaire, et, notamment, l'adhésion leucocytaire à médiation par VLA-4. Ces composés sont utiles pour traiter chez des mammifères, notamment chez l'homme, des maladies inflammatoires telles que l'asthme, la maladie d'Alzheimer, l'athérosclérose, le syndrome démentiel lié au SIDA, le diabète, les maladies intestinales inflammatoires, la polyarthrite rhumatoïde, la transplantation des tissus, les métastases tumorales et l'ischémie myocardique. Ces composés peuvent également être administrés pour traiter des maladies cérébrales inflammatoires telles que la sclérose en plaques.
front page image
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW
African Regional Intellectual Property Organization (ARIPO) (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)